The ax vaccine chief reveals that the “data” requirements of RFK Jr.

Dr. Peter Marks, a leader of vaccine at the Food and Drug Administration (FDA) who submitted his resignation last week, revealed some of the requests of the Secretary of Health, Robert F. Kennedy Jr., who made his position untenable.

Marks left his job as director of the Center for Biologics Evaluation and Research last week after being informed that if he would not resign, he would be dismissed. He had been in his position since 2016 and played a key role in the supervision of the development and regulation of vaccines during the COVVI-19 pandemic.

Talk to The Wall Street Journal Before his last day in the role of Saturday, Marks revealed that the Kennedy team had looked for non-existent data that they could use to justify the anti-vaccine stories that Kennedy has become known.

Marks told the newspaper: “I can never lighten someone other than to follow science as we see it. This does not mean that I can just turn around and take conspiracy theories and justify them. ”

Since the appointment by President Donald Trump of Kennedy to the role of the Secretary of Health and Social Services, thousands of employees of the department have been dismissed in the context of the reduction of general government staff of Elon Musk. In addition, Kennedy hired the discredited anti -vaxxer David Geier as senior data analyst so that he can study the “link” between vaccines and autism – a link that has already been largely and deepened by many other studies.

Marks has described Kennedy’s mandate so far as “very frightening” and said he was concerned to dismiss so many employees, saying to Newspaper, “They broke something without real plans to repair it, because people who were breaking had no idea.”

He continued: “They dismantled the place without having a manual of instructions on how to put it together.”

Despite these concerns, Marks initially attempted to work with Kennedy, offering listening sessions on vaccines and making information on clear vaccination for parents and doctors. However, this does not seem to be sufficient for Kennedy, whose team has quickly started to ask for data that does not exist to legitimize the anti-vaccine beliefs of Kennedy.

After the Kennedy team asked for data on cases of swelling of the brain and death caused by the measles vaccine – data that does not exist, because there was no case of this type in the United States – the objects concluded “that there was no appreciation to have someone who was rigorously focused on science within the organization”.

In response, an HHS official said that Marks had no place in the FDA if he “did not want to find himself behind the restoration of science to his gold standard and promote radical transparency”.

Marks also revealed that Kennedy is interested in weakening the regulations around unproven stem cell treatments, which he described as “potentially dangerous”, adding: “these stem cells, if they are badly made, they can harm people”.

People familiar with the case said to Newspaper The fact that Kennedy had long planned to withdraw the grades from his position, thanks to at least in part to the lack of support from Marks among those of Trump and Kennedy’s interior circles, including many anti-vacuum groups with which Kennedy has worked in the past who believes that Marks has precipitated the permits of cocvid-9 vaccines.

Del Bigtree, the former communications chief of Kennedy, who is also CEO of the anti-Vax informed consent network, said about Marks: “It represents everything that does not go with the regulatory organizations of our government.” The newly appointed FDA commissioner, Marty Makary, also argued the decision to develop the notes.

During the week since the resignation of Marks, the FDA has already shown signs of implementation of the Kennedy agenda by missing a key deadline to approve a COVVI-19 vaccination of Novavax. Marks said to Newspaper That if he had not already resigned, he would have done it after this deadline. Referring to nominees with political motivation to the FDA, Marks said: “Politicians should not have been involved. There was no controversy. Revision staff agreed that it was approval. ”